# Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

> **NCT05031949** · PHASE1 · UNKNOWN · sponsor: **Zhang Bi Xiang, MD** · enrollment: 20 (estimated)

## Conditions studied

- Combinational Immunotherapy
- Hepatocellular Carcinoma Non-Resectable
- Hyperbaric Oxygen Therapy

## Interventions

- **COMBINATION_PRODUCT:** hyperbaric oxygen therapy plus Camrelizumab

## Key facts

- **NCT ID:** NCT05031949
- **Lead sponsor:** Zhang Bi Xiang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031949, "Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05031949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*